DIA

DIA/TUFTS CSDD STUDY OVERVIEW

ASSESSING PARTICIPANT COMPENSATION PRACTICES AND THEIR ASSOCIATION WITH CLINICAL TRIAL PERFORMANCE

STUDY AIMS

The Drug Information Association (DIA) and the Tufts Center for the Study of Drug Development (Tufts CSDD) will be collaborating to conduct a new study that builds on the DIA Consortium's recently completed participant compensation landscape analysis.

This new study will assess (1) how participant compensation is derived and implemented — overall and by therapeutic area — and (2) the relationship between compensation practices and clinical trial performance outcomes (e.g., enrollment diversity, recruitment and retention rates, enrollment cycle times).

The results of this study will offer valuable benchmark descriptive data and actionable insights into optimizing compensation practices.

METHODS

Tufts CSDD and DIA, working collaboratively with the Participating Companies, will perform a mixed methods primary research study. Tufts CSDD and DIA will conduct in-depth interviews with clinical operations professionals from participating companies to understand compensation practices and how compensation levels are derived. Next, Tufts CSDD and DIA will facilitate a data collection exercise among participating companies.

Each participating company will provide data on 12 recently completed protocols (4 each from Phase I, II and III). The proposed data provided will include:

- Therapeutic area
- Phase
- Compensation amount
- Compensation components (e.g., participation payment, appreciation, completion bonus, expense reimbursement, and whether reimbursements are clearly separated from other payments)
- Protocol characteristics (e.g., endpoints, visits, procedures, procedure types, study duration, total patients enrolled)
- Clinical trial outcomes (e.g., overall and monthly enrollment speed, enrollment diversity, retention rates, protocol amendments and deviations)
- Number and types of investigative sites engaged

Tufts CSDD will analyze the results and evaluate compensation practices and their impact on clinical trial performance overall, by therapeutic area and by level of protocol scope and complexity. Analyses will look at within and between participating company differences and will identify factors and best practices associated with higher levels of recruitment and retention effectiveness and enrollment diversity. The participating companies, the

DIA and Tufts CSDD will meet virtually to review and discuss the preliminary results of the analysis. Following the preliminary results meeting, refinements and additional analyses will be performed.

DELIVERABLES

- Each participating company will receive a custom report comparing their practices with the aggregated working group benchmark. The benchmark data will always be presented in the aggregate, no individual company will ever be identified.

- A summary report will also be prepared and distributed to all participating companies.

- Participating company members, the DIA, and Tufts CSDD will look to co-author papers and to co-present the results and the implications at conferences, meetings, and webinars.

TIMELINE

Milestone	Targeted Completion Date
Study Initiation	February 2025
Data collection instrument; in-depth interview guide	March 2025
Interviews Conducted; Sponsor Data Collected	June 2025
Preliminary results review (DIA Annual Meeting)	June 2025
Final and custom company reports	August 2025
Manuscript submitted to TIRS	Early September 2025
Co-presentations at global industry conferences	Beginning October 2025

** The mentioned dates serve as suggested timelines, the study's kickoff contingent upon securing commitment from at least 10 companies.*

BUDGET

We are looking for a minimum of 10 and a maximum of 15 participating sponsor companies to each provide $23,000 in funding.